Safety and Tolerability Analysis of Combining Desmopressin With Docetaxel for the Treatment of Castration-Resistant Prostate Cancer
试验速览
- 阶段
- 早期 1 期
- 入组人数
- 10
- 主要终点
- Number of subjects presenting with AEs within a 21-day period of time post Desmopressin/Docetaxel treatment; nature and severity of AEs (as per Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03, Appendix B).
研究概览
简要总结
This is a single site, prospective, Phase 1 pilot trial intended to evaluate the safety and tolerability of adding one IV dose of Desmopressin to CRPC subjects at least 30 minutes prior to commencing standard IV Docetaxel treatment7,8.
详细描述
Following Desmopressin/Docetaxel treatment subjects will be subjected to routine medical oncology follow-up, including clinical appointments, laboratory and imaging workup as well as additional Docetaxel therapy every 21 days as indicated.
An additional study clinical appointment with blood work will be organized two days post Desmopressin/Docetaxel treatment. Furthermore, for detailed documentation of AEs during the first 21 days following Desmopressin/Docetaxel therapy, subjects will be assessed weekly via phone, and in person by the investigator/treating medical oncologist before the second dose of docetaxel.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •A subject will be considered eligible for inclusion in this study only if all of the following criteria apply:
- •Men over 18 years of age with histologically confirmed adenocarcinoma of the prostate.
- •Signed Informed Consent Form indicating that the subject understands the purpose of, and procedures required for, the study and is willing to participate in the study.
- •Castration-resistant stage of disease about to be treated with Docetaxel.
- •Baseline laboratory values as stated below:
- •Absolute neutrophil count ≥1.5 x 109/L;
- •Platelet count ≥125 x 109/L;
- •Creatinine ≤1.5 x upper limit of normal;
- •Urea ≤1.5 x upper limit of normal;
- •Bilirubin ≤1.1 x upper limit of normal (unless elevated secondary to conditions such as Gilbert's disease);
- •Aspartate transaminase (AST) ≤1.5 x upper limit of normal;
- •Alanine transaminase (ALT) ≤1.5 x upper limit of normal;
- •Castrate serum testosterone level (< 1.7 nmol/L).
排除标准
- •A subject will not be eligible for inclusion in this study if any of the following criteria apply:
- •Known Desmopressin intolerability.
- •Any state of known congestive heart disease (CHF class >1).
- •Sodium blood levels < 135 mEq/ml at enrollment.
- •Eastern Cooperative Oncology Group (ECOG) performance status >
- •Moderate or severe chronic kidney disease (eGFR <60 mL/min).
- •Prior use of docetaxel for CRPC.
- •≤30 days prior to study treatment received or had:
- •Transfusion (platelets or red blood cells), or hematopoetic growth factors;
- •Any type of chemotherapy;
- •Any form of hormonal treatment with the exception of the continuous GnRH analogues required to maintain castrate state;
- •Corticosteroid treatment equivalent to >10 mg of Prednisone orally daily;
- •An investigational agent for prostate cancer;
- •Ongoing Desmopressin therapy at enrollment;
- •Major surgery.
- •Current use of: Clofibrate, Chlorpropamide, Carbamazepine, Demeclocycline, Lithium, or Norepinephrine.
- •History of or current documented brain metastasis or carcinomatous meningitis, treated or untreated (brain imaging for asymptomatic subjects is not required).
- •Current symptomatic cord compression requiring surgery or radiation therapy (once successfully treated and there has been no progression, subjects are eligible for the study).
- •Uncontrolled medical conditions such as diabetes mellitus, angina pectoris, serious cardiac arrhythmia, severe hypertension, or active infection requiring systemic antibiotics, or any event such as myocardial infarction, cerebrovascular accident, or pulmonary embolism within 3 months prior to protocol therapy, as well as any significant concurrent medical illness that in the opinion of the Investigator would preclude protocol therapy.
研究组 & 干预措施
Desmopressin
Aim to evaluate the safety and tolerability of Desmopressin in CRPC subjects starting Docetaxel treatment.
干预措施: Desmopressin (Drug)
结局指标
主要结局
Number of subjects presenting with AEs within a 21-day period of time post Desmopressin/Docetaxel treatment; nature and severity of AEs (as per Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03, Appendix B).
时间窗: 12 months
Number of subjects presenting with AEs within a 21-day period of time post Desmopressin/Docetaxel treatment; nature and severity of AEs (as per Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03, Appendix B). The proportion of subjects presenting with hyponatremia at 48-hour time point; severity of hyponatremia as per CTCAE Version 4.03 (Appendix B).
次要结局
未报告次要终点